Why is Alembic Pharma falling/rising?

As of 04-Jul, Alembic Pharmaceuticals Ltd. is currently priced at 999.40, reflecting a decrease of 9.0 points or 0.89%. The stock has underperformed its sector by 1.4% today, despite trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, Alembic Pharma has shown a return of 2.59%, while its year-to-date performance is down by 5.64%. The company has a low Debt to EBITDA ratio of 0.67 times, indicating a strong ability to service debt, and it is trading at a discount compared to its peers. However, the stock's profits have fallen by 7% over the past year, which may contribute to the current decline in price, alongside a significant drop in investor participation, with delivery volume falling by 77.8% against the 5-day average.
In the broader market context, Alembic Pharmaceuticals' short-term return of 2.59% over the past week contrasts with the Sensex, which has decreased by 0.74% during the same period. This suggests that while the stock has been performing relatively better than the benchmark recently, its year-to-date decline of 5.64% is notable compared to the Sensex's increase of 6.77%. The high institutional holdings at 20.37% may provide some stability, as these investors typically have more resources to analyze the company's fundamentals. However, the overall market sentiment and the company's recent profit decline appear to be weighing on its stock price.